Innovacell

Focus: Innovacell is a biotechnology company specializing in cell and gene therapy treatments for incontinence and regenerative medicine indications. The company operates as a private biotech firm based in Austria with a focused pipeline across multiple therapeutic areas.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Innovacell

AI assessmentNot Hiring

No open roles listed right now. Follow Innovacell to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

RCS-01

Intrinsic Aging of Skin

Phase 1

Clinical Trials (1)

NCT02391935Study of Intradermal Injections of RCS-01 in Male and Female Subjects

Phase 1

Help build intelligence for Innovacell

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a Phase 3 program (aSMDC for fecal incontinence) with clear regulatory pathway and commercial potential
Pioneer cell therapy innovation across diverse applications—incontinence, dermatology, hair loss, and tendon repair—offering broad scientific exposure
Join a specialized, research-driven team at the forefront of autologous cell therapy with multiple clinical-stage assets

Watch Out For

Company has zero active job postings, signaling minimal near-term hiring and potential constrained growth trajectory
Private funding and financial data are undisclosed, creating visibility risk around cash runway and sustainability

Generated by Claude from Innovacell's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Transurethral intrasphincteric autologous myoblast implantation

Stress Urinary Incontinence

Phase 1/2

Clinical Trials (1)

NCT01355133Safety and Efficacy Study of Intrasphincteric Autologous Myoblast Injection to Treat Stress Urinary Incontinence

Phase 1/2

Human autologous hair follicle cells

Androgenetic Alopecia

Phase 1/2

Clinical Trials (1)

NCT01286649Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia

Phase 1/2